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Abstract
Background: Although many risk models have been tested in patients who undergo extracorporeal membrane
oxygenation, few have been assessed for patients who received veno-arterial extracorporeal membrane oxygenation
(VA-ECMO) support in the emergency department (ED). This study aimed to successfully predict outcomes of patients
with cardiac or noncardiac failure who received VA-ECMO in the ED within 24 hours of arrival at the ED.
Method: This retrospective, observational cohort study included 154 patients, who were classified as cardiac (n = 127)
and noncardiac (n = 27) patients and received VA-ECMO within 24 hours after arrival at the China Medical University
Hospital ED in Taiwan between January 2009 and September 2014. We recorded mechanical ventilation settings,
arterial blood gases, laboratory parameters including plasma lactate level, requirement of catecholamines, and risk
scores at time of ECMO initiation. ECMO and mechanical ventilation support duration, length of stay in the hospital,
and 90-day mortality data were also examined.
Results: The overall mortality rate was 64.9 %. We used “survival after veno-arterial ECMO (SAVE)” scores to assess
survival prediction in survival and nonsurvival groups, which was statistically different (–3.2 vs. –8.3, p <0.001).
According to multivariate Cox proportional regression of survival, lactate (hazard ratio [HR] = 1.01, 95 % confidence
interval [CI], 1.01–1.01, p <0.001) and SAVE score (HR = 0.92, [95 % CI, 0.88–0.96], p = 0.001) were independent predictors
of outcome. Excellent discrimination (area under curve (AUC) = 0.843) was observed when lactate and SAVE score were
combined, which we referred to as “the modified SAVE score.”
Conclusions: Modified SAVE scores improved outcome prediction for patients who underwent urgent VA-
ECMO in the ED.
Keywords: Extracorporeal membrane oxygenation, Outcome, Emergency, Acute respiratory distress syndrome,
Cardiac failure, Critical care
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Background
It is essential to make a timely and accurate diagnosis for
patients who present to the emergency department (ED)
with acute respiratory failure or circulatory failure, and an
adequate treatment plan should be established based on
the initial diagnosis. For example, dyspnea with respiratory
failure is frequent in patients admitted to the ED, and
rapid deterioration, including sudden cardiac arrest, may
develop. However, immediate and accurate discrimination
of heart conditions from other causes of dyspnea remains
a clinical challenge, and approximately 20 % of patients
are misdiagnosed [1]. Due to this, extracorporeal mem-
brane oxygenation (ECMO), including veno-arterial (VA)
and veno-venous (VV) methods, can temporarily stabilize
such patients using mechanical devices and provide suffi-
cient time to obtain a definitive diagnosis [2]. VA-ECMO
enhances the survival rate of patients experiencing refrac-
tory cardiogenic shock [3], and VV-ECMO has been pro-
posed as a possible rescue therapy for patients with severe
acute respiratory failure that is refractory to conventional
therapy [4–6]. Moreover, the combination of cardiopul-
monary resuscitation (CPR) and VA-ECMO, which is
known as E-CPR, yields promising results, compared with
those of conventional CPR (C-CPR), with regard to pa-
tients experiencing in-hospital cardiac arrest (IHCA) or
out-of-hospital cardiac arrest (OHCA) [7].
Despite the increasing experience with ECMO and tech-
nical improvements, the mortality of patients who receive
ECMO remains high [2, 4, 8–10]. Furthermore, extended
use of ECMO, with its associated requirements for a well-
skilled ECMO team and resources may raise hospital costs
[6]. Therefore, early identification of mortality risk factors is
needed. Schmidt et al. recently developed the “predicting
death for severe area under curve on VV-ECMO (PRE-
SERVE)” score and the “respiratory extracorporeal mem-
brane oxygenation survival prediction (RESP)” score to
predict mortality of patients experiencing acute respiratory
distress syndrome (ARDS) [11, 12]. For cardiac ECMO,
lactate, bilirubin, and creatinine levels as well as postcar-
diotomy status have been shown to exhibit significant pre-
dictive value [13, 14]. Schmidt et al. also developed the
“Survival After Veno-arterial ECMO (SAVE)” score to pre-
dict survival after VA-ECMO for refractory cardiogenic
shock using 12 pre-ECMO parameters: age, weight, diagno-
sis, chronic renal failure, acute pre-ECMO organ failure,
peak inspiratory pressure, duration of intubation, pre-
ECMO cardiac arrest, pulse pressure before ECMO, dia-
stolic pressure before ECMO, HCO3 level before ECMO
and a constant value to add to all calculations of SAVE
score [15]. Different predictive parameters are used for E-
CPR patients [16].
Currently, not much is known by the time patients are
urgently indicated for ECMO support in the ED. Although
a number of risk models have been tested in patients who
receive ECMO, few models have been tested in a patient
population that specifically received ECMO support in the
ED [17]. In this situation, we want to know if pre-ECMO
scores could be used to assess patients receiving VA-
ECMO support, which is the most frequently used ECMO
mode in the ED.
This study was designed to assess the survival rate of
patients with both cardiac and noncardiac conditions
who received VA-ECMO in the ED within 24 hours of
admission to the ED at our institution. In addition, this
study seeks to determine if the SAVE score, which was
created to predict survival after VA-ECMO for refractory
cardiogenic shock, was applicable to patients who
received VA-ECMO in the ED and identify the risk pre-
dictors for 90-day mortality.
Methods
Identified patients
A retrospective review of a prospective database indicated
that 188 patients received ECMO within 24 hours after ar-
rival at the ED between January 2009 and September 2014
at the China Medical University Hospital in Taichung,
Taiwan. China Medical University Hospital is a medical
referral center that has 130 intensive care unit beds and
received 152,560 patient visits in the ED in 2014. After the
exclusion of 16 patients who received VV-ECMO, nine
patients with incomplete data, and nine patients who re-
ceived ECMO due to operation, the study population con-
sisted of 154 patients.
Daily routine of ECMO configurations
The criteria used for evaluating the need for VA-ECMO
to treat refractory circulatory failure was assessed as pre-
viously described [18]. The decision to initiate ECMO
was made by the emergency physician in charge in con-
junction with the ECMO team. The ECMO team was
available at all times and included a perfusionist, an
anesthesiologist, and a cardiovascular surgeon. After
consultation, the ECMO team evaluated whether or not
the patient was indicated for ECMO, and if necessary,
the ECMO device was transported to the ED within
15 min.
Outcome variables
Clinical details were retrospectively extracted from a pro-
spective record of the ECMO database. Demographics,
comorbidities, and reasons for ECMO were collected. Pa-
tients that required chest compressions in the ED were
defined as having IHCA, while patients that required chest
compressions prior to hospital arrival were defined as hav-
ing OHCA. The “cardiac cause” was specified as pumping
failure, and the “noncardiac cause” was defined as hypox-
emic respiratory failure with or without circulation failure,
most of which was due to ARDS.
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Mechanical ventilation settings, arterial blood gases, and
laboratory parameters, including plasma lactate level, re-
quirement of catecholamines, and risk scores (sequential
organ failure assessment [SOFA] and SAVE scores), were
recorded at the time of ECMO initiation. ECMO and
mechanical ventilation support duration, length of hospital
stay, and 90-day mortality data were also extracted. Fur-
thermore, the assessment of functional neurologic outcome
of survivors with cerebral performance category (CPC) [19]
was recorded. The five categories are: CPC 1, good cerebral
performance (normal life); CPC 2, moderate cerebral dis-
ability (disabled but independent); CPC 3, severe cerebral
disability (conscious but disabled and dependent); CPC 4,
coma/vegetative state (unconscious); CPC 5, brain death.
Statistical analyses
Continuous variables are expressed as median and inter-
quartile ranges (25th and 75th percentile) and categorical
variables are expressed as percentages. The chi-squared
and Mann-Whitney U test were used to detect differ-
ences between survivors and nonsurvivors for categor-
ical and continuous variables, respectively. Kaplan-Meier
curves and log-rank tests were used to assess time to
death from the date of ECMO initiation to the 90-day
survival for groups stratified according to SAVE score.
Cox proportional hazards models were used to evaluate
the univariate and multivariate hazard ratios (HR) for risk
predictors of 90-day mortality. A candidate variable with a
univariate p ≤0.05 was retained in the multivariable model.
Variables included in the multivariable model were ana-
lyzed by correlation matrix to detect multicollinearity.
When variables were associated with each other (i.e., pH
and lactate), only one was included in the analyses. For
practical purposes, continuous variables were converted
into categories for incorporation in the final logistic re-
gression model. The beta-coefficients were rounded to the
nearest integer by dividing by the smallest coefficient.
The predictive accuracy of the mortality by variant
index pre-ECMO was assessed using the area under the
receiver operating characteristic (ROC) curve. p <0.05
was considered statistically significant. All statistical ana-
lyses were performed using SPSS software version 17.0
(SPSS Inc., Chicago, IL, USA) or MedCalc version 15.6.1
(MedCalc, Mariakerke, Belgium).
Results
During the study period, we assessed 154 patients who
were an average age of 51.7 years (range, 38–69 years) and
of which 72.1 % were male who received ECMO support
within 24 hours of arrival at the ED. One hundred twenty-
seven patients received ECMO support due to cardiac
causes, and 27 patients received support due to noncardiac
causes (Fig. 1). A large proportion of patients with noncar-
diac causes were admitted because of ARDS. There were
54 patients who were ultimately discharged, and the overall
mortality rate was 64.9 %. A total of 64.6 % of patients with
cardiac cause and 66.7 % with noncardiac cause died.
Among the 54 survivors, 18 of 54 (33.3 %) had a CPC of 1;
13 of 54 (24.0 %) had a CPC of 2; 12 of 54 (22.2 %) had a
CPC of 3; and 11 of 54 (20.3 %) had a CPC of 4.
Baseline characteristics and comparative results of the
patients who survived and those who did not are shown
in Table 1. Before ECMO initiation, survivors were
younger in age (43.1 vs. 56.4 years, p <0.001) and had
less acidosis (pH 7.20 vs. 7.06, p <0.001); less hypercap-
nia (PaCO2 40.1 vs. 51.3 mmHg, p = 0.007); higher bicar-
bonate levels (HCO3
− 15.6 vs. 12.7 mmol/L, p = 0.001),
lower lactate levels (64.9 vs. 115.2 mg/dL, p <0.001),
higher platelet counts (216.8 vs. 184.9 × 103/μL, p =
0.036), and lower severity scores (SOFA score 8.7 vs.
10.5, p = 0.004). Additionally, the proportion of OHCA
was lower in the survival group (22.2 % vs. 41.0 %, p =
0.031). Sex, Charlson score, body mass index, PaO2/
FiO2, plateau pressure, and other laboratory data were
not significantly different among survivors and nonsur-
vivors. We assessed SAVE scores for survival prediction
in the two groups, which were statistically different (–
3.2 vs. –8.3, p <0.001).
Kaplan-Meier survival curves according to SAVE score
classes are plotted in Fig. 2. The log-rank test showed
significantly different risks between groups (p <0.001).
Fig. 1 Flowchart of enrolled subjects. A total of 154 patients received
urgent extracorporeal membrane oxygenation (ECMO) within 24 hours
after arrival at the emergency department (ED), including 127 patients
with cardiac causes and 27 patients with noncardiac causes. ARDS acute
respiratory distress syndrome, CCB calcium channel blocker, MMF
mycophenolate mofetil, OHCA out-of-hospital cardiac arrest, V-A mode
veno-arterial mode, V-V mode veno-venous mode
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However, it was challenging to discriminate survival
probabilities with SAVE scores in more severe risk clas-
ses (class IV and V).
By univariate analysis, age, OHCA, pH, HCO3
−, PaCO2,
lactate, platelet count, and SOFA and SAVE scores were
potential prognostic factors for 90-day mortality (Table 2).
Multivariate Cox proportional hazards regression of sur-
vival was conducted using these variables, revealing SAVE
score (HR = 0.92, [95 % CI, 0.88–0.96], p = 0.001) and lac-
tate level (HR = 1.01, [95 % CI, 1.01–1.01], p <0.001) to be
independent variables.
In the ROC curves used to predict 90-day mortality, the
SOFA score showed limited discrimination (area under
curve, AUC of SOFA score = 0.65), while lactate level and
SAVE score showed acceptable discrimination (AUC for
lactate = 0.79; AUC for SAVE score = 0.73) (Fig. 3).
Because lactate and SAVE score were both statistically
significant mortality predictors in the Cox proportional
hazards regression model and both showed acceptable
discrimination with ROC curves, we developed a new
Table 1 Intensive care scores and mechanical ventilation variables at the time of ICU admission
All patients (N = 154) Survivors (N = 54) Nonsurvivors (N = 100) p value
Age (yr) 51.7 (38.0–69.0) 43.1 (28.0–62.0) 56.4 (42.5–70.0) <0.001
Male (n, %) 111 (72.1) 35 (64.8) 76 (76) 0.103
Charlson score 0.8 (0–1.0) 0.6 (0–1.0) 1.0 (0–1.0) 0.18
Body mass index >30 kg/m2 (n, %) 23 (14.9) 7 (13.0) 16 (16.0) 0.79
Immunocompromised (n, %) 19 (12.3) 5 (9.3) 14 (14.0) 0.55
Pre-ECMO blood gases
pH 7.11 (6.97–7.24) 7.20 (7.07–7.31) 7.06 (6.92–7.18) <0.001
PaO2/FiO2 (mmHg) 144.9 (60.0–209.0) 146.7 (62.0–190.0) 144.0 (52.5–212.5) 0.21
PaCO2 (mmHg) 47.3 (32.0–59.0) 40.1 (31.0–51.0) 51.3 (32.5–67.5) 0.007
HCO3
- (mmol/L) 13.7 (10.2–17.7) 15.6 (13.2–18.4) 12.7 (9.1–16.6) 0.001
Mechanical ventilation
Plateau pressure (cmH2O) 29.5 (27.0–32.0) 28.5 (26.0–30.0) 30.0 (27.0–33.0) 0.06
Laboratory parameters
Lactate (mg/dL) 97.4 (56.0–125.1) 64.9 (40.0–75.0) 115.2 (75.3–144.4) <0.001
Hct (%) 39.4 (35.0–45.0) 39.6 (35.7–44.2) 39.3 (34.3–45.4) 0.93
Platelet count (× 103/μL) 196.1 (147.0–242.0) 216.8 (153.0–280.0) 184.9 (124.5–224.0) 0.036
Creatinine (mg/dL) 1.97 (1.09–1.95) 1.75 (0.98–1.90) 2.09 (1.14–2.06) 0.06
Bilirubin (mg/dL) 1.02 (0.50–0.91) 0.80 (0.50–0.81) 1.13 (0.50–0.93) 0.09
CRP 3.25 (0.31–2.15) 2.52 (0.22–1.21) 3.65 (0.33–3.28) 0.06
Vasopressors before ECMO (n, %) 134 (87.0) 26 (48.1) 81 (81.0) 0.21
Cardiac arrest before ECMO
IHCA (n, %) 62 (40.3) 18 (33.3) 44 (44.0) 0.09
OHCA (n, %) 53 (34.4) 12 (22.2) 41 (41.0) 0.031
SOFA score 9.8 (7.0–13.0) 8.7 (6.0–12.0) 10.5 (8.0–13.0) 0.004
SAVE score –6.5 (–10.0– –3.0) –3.2 (–7.0–2.0) –8.3 (–11.0– –5.0) <0.001
CRP C-reactive protein, ECMO extracorporeal membrane oxygenation, IHCA in-hospital cardiac arrest, OHCA out-of-hospital cardiac arrest, SAVE score Survival After
Veno-arterial ECMO score, SOFA score Sequential Organ Failure Assessment score, V-A mode veno-arterial mode, V-V mode veno-venous mode
Fig. 2 Kaplan-Meier survival curves according to different SAVE score
classes. SAVE score Survival After Veno-arterial Extracorporeal membrane
oxygenation score
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model that incorporated lactate data into the SAVE
score. Lactate level was dichotomized into groups of pa-
tients with levels <75 mg/dL and ≥75 mg/dL based on
data that has maximal Youden’s index. The odds ratios
(ORs) for both SAVE score (OR = 1.17, 95 % confidence
interval [CI]: 1.08–1.26, p <0.001) and lactate level (OR
= 8.74, 95 % CI: 3.81–20.06, p <0.001) were increased in
the logistic regression model (Table 3). The regression
coefficients for these two predictors were rounded to the
nearest integer risk score and summed to calculate the
modified SAVE scores in Table 3. For example, if the pa-
tient had a SAVE score of 5 and lactate level of 60 mg/
dl, his modified SAVE score would be 5 + 15 = 20.
Modified SAVE scores ranged from –35 to 32 and
were divided into five risk classes, referred to as class I
(score >10), class II (score 1 to 10), class III (score -4 to
0), class IV (score –10 to –5) and class V (score < -10).
The predicted 90-day mortality of patients with these
modified SAVE scores were 21, 48, 68, 90 and 96 %, re-
spectively. In the ROC curves used to predict 90-day
mortality, excellent discrimination (AUC = 0.84) was
seen for the modified SAVE score (Fig. 3).
Discussion
To the best of our knowledge, this is the first and
largest study focusing on patients who required VA-
ECMO to treat circulatory failure within 24 hours
after arrival at the ED. We tested the efficacy of the
SAVE score, which was originally created for patients
receiving VA-ECMO due to refractory cardiogenic
shock, and showed that SAVE scores were helpful
Table 2 Cox proportional hazards regression model analysis for prognostic factors of emergency ECMO use
Variables Univariate analysis Multivariate analysis
Hazard ratio (95 % CI) p value Hazard ratio (95 % CI) p value
SAVE score 0.92 (0.90-0.95) <0.001 0.92 (0.88–0.96) 0.001
SOFA score 1.11 (1.04–1.17) 0.001 0.96 (0.89–1.05) 0.37
Age (yr) 1.02 (1.01–1.03) <0.001 NEa
OHCA 1.77 (1.19–2.64) 0.005 1.13 (0.69–1.86) 0.62
Laboratory findings
PaCO2 (mmHg) 1.02 (1.01–1.03) 0.001 1.00 (0.99–1.01) 0.93
HCO3
- (mmol/L) 0.94 (0.91–0.97) 0.001 NEa
Lactate (mg/dL) 1.01 (1.01–1.01) <0.001 1.01 (1.01–1.01) <0.001
Platelet (x103/μL) 1.00 (0.99–1.00) 0.007 1.00 (1.00–1.00) 0.11
pH 0.07 (0.02–0.21) <0.001 NEb
CI confidence interval, ECMO extracorporeal membrane oxygenation, IHCA in-hospital cardiac arrest, OHCA out-of-hospital cardiac arrest, SAVE score Survival After
Veno-arterial ECMO score, SOFA score Sequential Organ Failure Assessment score,
aNot entered into the multivariate analysis because age and HCO3
- are involved in SAVE score
bNot entered into the multivariate analysis because of pH and lactate with high collinearity
Fig. 3 ROC curves for predicting 90-day mortality in patients who
receive emergency ECMO according to different variables. Various AUC
values were seen when predicting 90-day mortality: SOFA (green line) =
0.65, lactate (gray line) = 0.79, SAVE score (blue line) = 0.73, and “the
modified SAVE score” (combination of lactate and SAVE score)
(red line) = 0.84. AUC area under the curve, ROC curve receiver
operating characteristic curve, SAVE score Survival After Veno-
arterial Extracorporeal membrane oxygenation score, SOFA score
Sequential Organ Failure Assessment score
Table 3 Logistic regression model analysis and coefficients for







SAVE score 0.16 SAVE score 1.17 (1.08–1.26) <0.001
Lactate (mg/dL)
< 75 2.17 15 8.74 (3.81–20.06) <0.001
≥ 75 0
CI confidence interval, SAVE score Survival After Veno-arterial ECMO score,
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when used to assess patients receiving VA-ECMO in
the ED. In this study, we also created a strong pre-
dictive survival model specifically for patients receiv-
ing VA-ECMO using the combination of blood lactate
level and SAVE score, which we called the modified
SAVE score. This score resulted in best discrimination
in the mortality prediction model.
Although ECMO can provide total circulatory sup-
port and fully correct gas-exchange abnormalities, the
mortality of patients undergoing severe cardiogenic
shock or ARDS who receive urgent ECMO remains
high. In the CESAR trial, in which 180 patients with se-
vere ARDS were randomly assigned to receive ECMO,
the mortality in a 6-month period was 37 % [6]. For
cardiac ECMO patients, mortality rates reached 57–
80 % [13, 14]. In our 154 patients who underwent VA-
ECMO within 24 hours of arrival at the ED, including
127 and 27 patients with cardiac and noncardiac
causes, respectively, the mortality rates were 64.6 % and
66.7 %, respectively. The mortality rates were higher
than those in the Extracorporeal Life Support
Organization (ELSO) registry report (60 % for cardiac
ECMO and 44 % for respiratory ECMO) [20]. The high
percentage (74.7 %) of cardiac arrest before ECMO ini-
tiation in our patient population may explain the differ-
ences in survival. Furthermore, noncardiac patients
who received VA-ECMO in the ED usually were experi-
encing shock and/or cardiac arrest, which have worse
patient outcomes. This may explain the high mortality
rate of noncardiac patients in our study.
To avoid unnecessary use of ECMO, which might un-
necessarily consume resources and expose patients to pos-
sible ECMO complications, thorough consideration must
be used to identify the appropriate candidates for ECMO
support. Hence, a number of studies have established risk
scores to predict mortality in patients receiving ECMO.
The well-known PRESERVE and RESP scores designed by
Schmidt et al. were designed for patients with ARDS who
required VV-ECMO support [11, 12, 21]. Recently,
Schmidt et al. created the SAVE score, which yielded an
AUC value of 0.68 for patients supported by VA-ECMO
for refractory cardiogenic shock [15]. Since specifically an-
alyzed patients receiving VA-ECMO, we used the SAVE
score rather than PRESERVE or RESP scores in our
cohort to predict 90-day mortality and showed an accept-
able AUC value of 0.73. Additionally, SAVE score was
found to be an independent variable in the Cox propor-
tional hazards regression model. In our cohort, Kaplan-
Meier survival analysis by log-rank test for SAVE score
classes revealed significantly different survival times
among stratified patients. However, it was challenging to
totally discriminate survival within various SAVE score
classes (Fig. 2). Otherwise, by multivariate Cox propor-
tional hazards regression analysis, high pre-ECMO blood
lactate levels combined and low SAVE scores emerged as
risk factors of mortality.
Several studies have shown a close association between
high blood pre-ECMO lactate level and mortality in pa-
tients receiving ECMO for cardiac causes [22, 23].
Shorter CPR durations during E-CPR for IHCA or
OHCA lead to lower titers of lactate, higher survival
rates, and better neurologic outcomes [24]. However, in
our series, OHCA had no significant predictive value by
multivariate analysis when combined with lactate. Other-
wise, our study showed that increased lactate levels
gradually increased the hazard ratio, and with every in-
crease of 1 mg/dL, the mortality risk increased by 1 %.
Lactate levels discriminated survivors from nonsurvivors
with an AUC of 0.79. When lactate was combined with
SAVE score, the mortality prediction achieved the high-
est AUC of 0.84. Therefore, we developed an amalgam-
ation between these two variables called the modified
SAVE score. Using the modified SAVE score (score -35
to 32), we predicted survival of patients receiving VA-
ECMO support in the ED to reveal predicted 90-day
mortality ranging from 21 to 96 %.
This study is strengthened by the large number of in-
cluded patients. However, certain limitations should be
considered. First, it is a single-center retrospective study,
which could restrict the translation of our results to other
hospitals. Second, although we included only patients re-
ceiving VA-ECMO support in the ED, the underlying dis-
eases within our cohort were diverse. Nevertheless, it
stands that the modified SAVE score could be applied to
patients with circulatory failure even if a definitive diagno-
sis could not be obtained in time, which is not uncommon
in the ED. Third, we did not have enough patients to in-
ternally validate the model. Further research is needed to
better assess the external validity of the modified SAVE
score in a large independent cohort.
Conclusions
In conclusion, our study indicates that the combination
of blood lactate level and SAVE score, termed the modi-
fied SAVE score, results in improved discrimination of
outcome predictions for patients who receive VA-ECMO
support in the ED. The modified SAVE score will help
emergency or critical care physicians evaluate and treat
heterogeneous patients who were indicated for VA-
ECMO support with little information concerning the
cause of the critical condition.
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